Biotherapy and rheumatoid arthritis: A medico-economic evaluation from 2008 French Hospital Database

Joint Bone Spine

Volumn 79, Issue 1, 2012, Pages 96-97

  Maravic, Milka ^a   Baudens, Guy ^b   Sanchez, Jean Philippe ^b   Flipo, René Marc ^c   Toubiana, Laurent ^d,e   Landais, Paul ^d  

^a Léopold Bellan Hospital   (France)

^b Service de Rhumatologie   (France)

^c UNIV LILLE   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e INSERM   (France)

Author keywords

Biotherapy; France; Hospitalizations; Rheumatoid arthritis; Year 2008

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; INFLIXIMAB; RITUXIMAB;

ADULT; DATA BASE; DRUG COST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FRANCE; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; DATABASES, FACTUAL; DRUG SUBSTITUTION; FEMALE; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED;

EID: 84855687113     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.06.004     Document Type: Letter

References (10)

1. Smolen J.S., Landewé R., Breedveld F.C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.
2. Haute Autorité de Santé Quick Reference Guide. Rheumatoid arthritis: Diagnostic and initial management. September 2007: ; Treatment of established rheumatoid arthritis. September 2007: ; Medical. social and organizational aspect of management (excluding surgery and drugs). September 2007: http://www.has-sante.fr/portail/upload/docs/application/pdf/quick_reference_guide_rheumatoid_arthritis.pdf.
3. Site assurance maladie: Base des médicaments et information tarifaire: http://www.codage.ext.cnamts.fr/codif/bdm_it/index.php%3Fp_site=AMELI.
4. Journal Officiel. Arrêté du 14 mars 2011 pris pour l'application de l'article L.162-22-7-2 du Code de la Sécurité sociale. Journal Officiel; 23 mars 2011.
5. Site Agence Technique de l'information sur l'hospitalisation: http://www.atih.sante.fr/.
6. Société française de rhumatologie: http://sfr.larhumatologie.com/recherche/Promoteurs/LesRegistres/index.phtml.
7. Gottenberg J.E., Ravaud P., Bardin T., et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010, 62:2625-2632.
8. Watson K., Symmons D., Griffiths I., et al. The British Society for Rheumatology biologic registers. Ann Rheum Dis 2005, 64:iv42-iv43.
9. Kobelt G., Lindgren P. Geborek P. Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data. Scand J Rheumatol 2009, 38:409-418.
10. Brennan A., Bansback N., Nixon R., et al. Modelling the cost effectiveness of TNF-α antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology 2007, 46:1345-1354.